Bone void filler guidance finalized
This article was originally published in The Gray Sheet
Executive Summary
"Bone void filler devices composed of alternate materials may be demonstrated to be substantially equivalent...to the resobable calcium salt bone void filler device identified in this guidance," FDA notes in its 1Class II special controls guidance on bone void fillers. However, FDA cautions that the guidance addresses only submission requirements and risk mitigation measures for resorbable calcium salt intended to fill bony gaps not intrinsic to the stability of the bony structure. Posted on the CDRH website May 28, the final guidance supersedes a Feb. 7, 2002 draft issued following a petition to reclassify Wright Medical Technologies' Osteoset into Class II (2"The Gray Sheet" Feb. 11, 2002, p. 11)...
You may also be interested in...
FDA Regulatory News In Brief
Device tracking: 1Medical device tracking final rule amending 1993 reg to reflect changes under FDAMA is effective May 9. No revisions are made to the April 25, 2000 proposed rule (2"The Gray Sheet" May 1, 2000, In Brief). The rule "makes no revisions to the regulation's existing system and content tracking requirements, the current obligations of persons other than device manufacturers, such as distributors, records and inspection requirements and existing record retention requirements." A final guidance on medical device tracking was issued Jan. 24, 2000...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.